Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Recent studies have demonstrated great therapeutic potential of educating and unleashing our own immune system for cancer treatment. However, there are still major challenges in cancer immunotherapy, including poor immunogenicity of cancer vaccines, off-target side effects of immunotherapeutics, as...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-08-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/3/3/662 |
id |
doaj-e71b397ec3f247dfb214fe7427020905 |
---|---|
record_format |
Article |
spelling |
doaj-e71b397ec3f247dfb214fe74270209052020-11-24T22:28:15ZengMDPI AGVaccines2076-393X2015-08-013366268510.3390/vaccines3030662vaccines3030662Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyYuchen Fan0James J. Moon1Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USADepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USARecent studies have demonstrated great therapeutic potential of educating and unleashing our own immune system for cancer treatment. However, there are still major challenges in cancer immunotherapy, including poor immunogenicity of cancer vaccines, off-target side effects of immunotherapeutics, as well as suboptimal outcomes of adoptive T cell transfer-based therapies. Nanomaterials with defined physico-biochemical properties are versatile drug delivery platforms that may address these key technical challenges facing cancer vaccines and immunotherapy. Nanoparticle systems have been shown to improve targeted delivery of tumor antigens and therapeutics against immune checkpoint molecules, amplify immune activation via the use of new stimuli-responsive or immunostimulatory materials, and augment the efficacy of adoptive cell therapies. Here, we review the current state-of-the-art in nanoparticle-based strategies designed to potentiate cancer immunotherapies, including cancer vaccines with subunit antigens (e.g., oncoproteins, mutated neo-antigens, DNA and mRNA antigens) and whole-cell tumor antigens, dendritic cell-based vaccines, artificial antigen-presenting cells, and immunotherapeutics based on immunogenic cell death, immune checkpoint blockade, and adoptive T-cell therapy.http://www.mdpi.com/2076-393X/3/3/662cancer immunotherapynanotechnologycancer vaccinelymphoid drainingadjuvantdendritic cellimmune checkpointadoptive cell therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuchen Fan James J. Moon |
spellingShingle |
Yuchen Fan James J. Moon Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy Vaccines cancer immunotherapy nanotechnology cancer vaccine lymphoid draining adjuvant dendritic cell immune checkpoint adoptive cell therapy |
author_facet |
Yuchen Fan James J. Moon |
author_sort |
Yuchen Fan |
title |
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy |
title_short |
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy |
title_full |
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy |
title_fullStr |
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy |
title_full_unstemmed |
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy |
title_sort |
nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2015-08-01 |
description |
Recent studies have demonstrated great therapeutic potential of educating and unleashing our own immune system for cancer treatment. However, there are still major challenges in cancer immunotherapy, including poor immunogenicity of cancer vaccines, off-target side effects of immunotherapeutics, as well as suboptimal outcomes of adoptive T cell transfer-based therapies. Nanomaterials with defined physico-biochemical properties are versatile drug delivery platforms that may address these key technical challenges facing cancer vaccines and immunotherapy. Nanoparticle systems have been shown to improve targeted delivery of tumor antigens and therapeutics against immune checkpoint molecules, amplify immune activation via the use of new stimuli-responsive or immunostimulatory materials, and augment the efficacy of adoptive cell therapies. Here, we review the current state-of-the-art in nanoparticle-based strategies designed to potentiate cancer immunotherapies, including cancer vaccines with subunit antigens (e.g., oncoproteins, mutated neo-antigens, DNA and mRNA antigens) and whole-cell tumor antigens, dendritic cell-based vaccines, artificial antigen-presenting cells, and immunotherapeutics based on immunogenic cell death, immune checkpoint blockade, and adoptive T-cell therapy. |
topic |
cancer immunotherapy nanotechnology cancer vaccine lymphoid draining adjuvant dendritic cell immune checkpoint adoptive cell therapy |
url |
http://www.mdpi.com/2076-393X/3/3/662 |
work_keys_str_mv |
AT yuchenfan nanoparticledrugdeliverysystemsdesignedtoimprovecancervaccinesandimmunotherapy AT jamesjmoon nanoparticledrugdeliverysystemsdesignedtoimprovecancervaccinesandimmunotherapy |
_version_ |
1725747247329574912 |